Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Sino Biopharmaceutical (SBMFF) Price & Analysis

SBMFF Stock Chart & Stats

$0.62-$0.01(-0.96%)
At close: 4:00 PM EDT
$0.6$0.65$0.7$0.755 Aug21 Aug9 Sep18 Sep29 Sep19 Oct
Day’s Range
$0.60 - $0.63
52-Week Range
$0.53 - $0.98
Previous Close
$0.62
Volume
70
Average Volume (3M)
70
Market Cap
$10.94B
Enterprise Value
$83.38B
Total Cash (Recent Filing)
$27.58B
Total Debt (Recent Filing)
$17.17B
Price to Earnings (P/E)
30.8
Beta
0.20
Next Earnings
Apr 01, 2027
EPS Estimate
0.01
Next Dividend Ex-Date
N/A
Dividend Yield
2.43%

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Gross Margin

Revenue re-acceleration alongside consistently high gross margins indicates stronger demand and meaningful product economics. This combination can support reinvestment in research, regulatory development, and commercialization while giving the portfolio a durable base for growth over the next several quarters.

Cash Generation

Operating and free cash flow increased in 2025, with free cash flow rebounding sharply and remaining well supported relative to net income. Healthy cash conversion gives Sino Biopharm more internally generated capacity to fund product development, launches, and balance-sheet needs.

Portfolio And Market Reach

A portfolio spanning branded generics and innovative medicines across multiple therapeutic areas, sold through hospitals, pharmacies, and other channels, provides several avenues for commercialization. This breadth can reduce reliance on one product or route to market and supports durable access to healthcare demand.

Bears Say

Declining Net Profitability

The decline in net margin from about 12.1% to 7.4% shows that strong gross economics are not fully translating into bottom-line earnings. If this pressure persists, it can constrain reinvestment, weaken returns on equity, and make reported profit less dependable over the medium term.

Rising Leverage

Debt-to-equity rose from about 0.31 to 0.52, making the capital structure less conservative even though leverage remains moderate overall. The increase reduces financial flexibility and could divert future cash toward debt servicing if profitability remains under pressure.

Operating Cash Flow Coverage

Cash-flow coverage of operating profit was only about 0.37 in 2025, indicating a meaningful gap between reported operating earnings and cash generation. Working-capital or non-cash effects may therefore create variability in funding capacity and reduce confidence in earnings-to-cash conversion.

Sino Biopharmaceutical News

SBMFF FAQ

What was Sino Biopharmaceutical’s price range in the past 12 months?
Sino Biopharmaceutical lowest stock price was $0.53 and its highest was $0.98 in the past 12 months.
What is Sino Biopharmaceutical’s market cap?
Sino Biopharmaceutical’s market cap is $10.94B.
When is Sino Biopharmaceutical’s upcoming earnings report date?
Sino Biopharmaceutical’s upcoming earnings report date is Apr 01, 2027 which is in 151 days.
How were Sino Biopharmaceutical’s earnings last quarter?
Sino Biopharmaceutical released its earnings results on Aug 19, 2026. The company reported $0.028 earnings per share for the quarter, beating the consensus estimate of $0.018 by $0.01.
Is Sino Biopharmaceutical overvalued?
According to Wall Street analysts Sino Biopharmaceutical’s price is currently Undervalued.
Does Sino Biopharmaceutical pay dividends?
Sino Biopharmaceutical pays a Semiannually dividend of $0.009 which represents an annual dividend yield of 2.43%. See more information on Sino Biopharmaceutical dividends here
What is Sino Biopharmaceutical’s EPS estimate?
Sino Biopharmaceutical’s EPS estimate is 0.01.
How many shares outstanding does Sino Biopharmaceutical have?
Sino Biopharmaceutical has 18,682,953,000 shares outstanding.
What happened to Sino Biopharmaceutical’s price movement after its last earnings report?
Sino Biopharmaceutical reported an EPS of $0.028 in its last earnings report, beating expectations of $0.018. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sino Biopharmaceutical?
Currently, no hedge funds are holding shares in SBMFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology